The DOI matches its Crossref record; 34 of the 36 references it cites were found in a registry or an index.
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Open accessAbstract
BACKGROUND: Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with advanced renal-cell carcinoma. This randomized, open-label, phase 3 study compared nivolumab with everolimus in patients with renal-cell carcinoma who had received previous treatment. METHODS: A total of 821 patients with advanced clear-cell renal-cell carcinoma for which they had received previous treatment with one or two regimens of antiangiogenic therapy were randomly assigned (in a 1:1 ratio) to receive 3 mg of nivolumab per kilogram of body weight intravenously every 2 weeks or a 10-mg everolimus tablet orally once daily. The primary end point was overall survival. The secondary end points included the objective response rate and safety. RESULTS: The median overall survival was 25.0 months (95% confidence interval [CI], 21.8 to not estimable) with nivolumab and 19.6 months (95% CI, 17.6 to 23.1) with everolimus. The hazard ratio for death with nivolumab versus everolimus was 0.73 (98.5% CI, 0.57 to 0.93; P=0.002), which met the prespecified criterion for superiority (P≤0.0148). The objective response rate was greater with nivolumab than with everolimus (25% vs. 5%; odds ratio, 5.98 [95% CI, 3.68 to 9.72]; P<0.001). The median progression-free survival was 4.6 months (95% CI, 3.7 to 5.4) with nivolumab and 4.4 months (95% CI, 3.7 to 5.5) with everolimus (hazard ratio, 0.88; 95% CI, 0.75 to 1.03; P=0.11). Grade 3 or 4 treatment-related adverse events occurred in 19% of the patients receiving nivolumab and in 37% of the patients receiving everolimus; the most common event with nivolumab was fatigue (in 2% of the patients), and the most common event with everolimus was anemia (in 8%). CONCLUSIONS: Among patients with previously treated advanced renal-cell carcinoma, overall survival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than with everolimus. (Funded by Bristol-Myers Squibb; CheckMate 025 ClinicalTrials.gov number, NCT01668784.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Immune checkpoint blockade (ICB), especially targeting the inhibitory receptor programmed cell death 1 (PD-1) expressed on CD8+ T cells, is a highly effective immunotherapy for various cancers.”
From Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredIn the citing paper
“Primary resistance to ICI is common in patients with both RCC and NSCLC, ranging from 35% to 44% and remains unpredictable [1,3].”
In the citing paper
“Response rates range from 15 to 30% (in most solid tumors) to 45–60% (in melanoma and MSI-H tumors).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [3]
In the citing paper
“At present, antibodies blocking PD-1 or its ligand PD-L1 have been approved to treat various solid and hematologic malignancies (Table 1) [7–12].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationHapeman, D. E., & Agresti, A. (1991) · Technometrics · doi:10.1080/00401706.1991.10484817 · Cited by 9,407
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationTHE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
Clopper, C. J., & Pearson, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,327
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G. R., Carducci, M. A., Tomczak, P., Dutcher, J. P., Figlin, R. A., Kapoor, A., Starosławska, E., Sosman, J. A., McDermott, D. F., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,645
Self-citation
Cited by
Sorted by citations
Items 901–1,000 of 1,022
Ohmura, H., Yamaguchi, T., Hanamura, F., Ito, M., Makiyama, A., Uchino, K., Shimokawa, H., Tamura, S., Esaki, T., Mitsugi, K., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0810-1 · Cited by 80
Maillet, D., Corbaux, P., Stelmes, J., Dalle, S., Locatelli-Sanchez, M., Perier‐Muzet, M., Duruisseaux, M., Kiakouama-Maleka, L., Freyer, G., Boespflug, A. M., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.03.017 · Cited by 79
Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience
Fortes, B. H., Liou, H., & Dalvin, L. A. (2020) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-316970 · Cited by 79
Chan, J. K., Brady, W. E., Monk, B. J., Brown, J., Shahin, M. S., Rose, P. G., Kim, J., Secord, A. A., Walker, J. L., & Gershenson, D. M. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.05.029 · Cited by 79
Systemic Immunotherapy for the Treatment of Brain Metastases
Cohen, J. V., & Kluger, H. M. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00049 · Cited by 78
Nadal, R., Amin, A., Geynisman, D. M., Voss, M. H., Weinstock, M., Doyle, J., Zhang, Z., Viúdez, A., Plimack, E. R., McDermott, D. F., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw160 · Cited by 78
Self-citationDumont, C., Jacquier, A., Verine, J., Noël, F., Goujon, A., Wu, C., Hung, T., Desgrandchamps, F., Culine, S., Carosella, E. D., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0764 · Cited by 78
Choosing The Right Animal Model for Renal Cancer Research
Sobczuk, P., Brodziak, A., Khan, M. I., Chhabra, S., Fiedorowicz, M., Wełniak-Kamińska, M., Synoradzki, K. J., Bartnik, E., Cudnoch‐Jędrzejewska, A., & Czarnecka, A. M. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100745 · Cited by 81
Humbert, O., & Chardin, D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.566297 · Cited by 79
Updates on Immunotherapy and Immune Landscape in Renal Clear Cell Carcinoma
Kim, M., Jin, Z., Kolb, R. H., Borcherding, N. C., Chatzkel, J. A., Falzarano, S. M., & Zhang, W. (2021) · Cancers · doi:10.3390/cancers13225856 · Cited by 80
Immune checkpoint inhibitor-related pneumonitis: research advances in prediction and management
Lin, M., Zang, D., Liu, C., Han, X., & Chen, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1266850 · Cited by 79
Innate and acquired immune surveillance in the postdissemination phase of metastasis
Velozo, H. G., Robles, I., & Werb, Z. (2017) · FEBS Journal · doi:10.1111/febs.14325 · Cited by 78
The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population
Sattar, J., Kartolo, A., Hopman, W. M., Lakoff, J. M., & Baetz, T. D. (2018) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2018.07.015 · Cited by 77
Prognostication in Kidney Cancer: Recent Advances and Future Directions
Graham, J., Dudani, S., & Heng, D. Y. C. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.0147 · Cited by 79
Zhou, B., Guo, L., Zhang, B., Liu, S., Zhang, K., Yan, J., Zhang, W., Yu, M., Chen, Z., Xu, Y., et al. (2019) · PubMed Central · Cited by 77
Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors
Alaiwi, S. A., Nassar, A. H., Xie, W., Bakouny, Z., Berchuck, J. E., Braun, D. A., Baca, S. C., Nuzzo, P. V., Flippot, R., Mouhieddine, T. H., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0866 · Cited by 80
Self-citationRiaz, I. B., He, H., Ryu, A. J., Siddiqi, R. L., Naqvi, S. A. A., Yao, Y., Husnain, M., Narasimhulu, D. M., Mathew, J., Sipra, Q. U. A. R., et al. (2021) · European Urology · doi:10.1016/j.eururo.2021.03.016 · Cited by 79
Computational immunogenomic approaches to predict response to cancer immunotherapies
Addala, V., Newell, F., Pearson, J. V., Redwood, A., Robinson, B. W. S., Creaney, J., & Waddell, N. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00830-6 · Cited by 79
Pulmonary toxicity of immune checkpoint immunotherapy
Ghanbar, M., & Suresh, K. S. (2024) · Journal of Clinical Investigation · doi:10.1172/jci170503 · Cited by 80
Holmgaard, R., Brachfeld, A., Gasmi, B., Jones, D. R., Mattar, M. S., Doman, T. N., Murphy, M. Y., Schaer, D., Wolchok, J. D., & Merghoub, T. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1151595 · Cited by 80
Maxwell, R., Luksik, A. S., Garzón-Muvdi, T., Hung, A. L., Kim, E. S., Wu, A., Xia, Y., Belcaid, Z., Gorelick, N. L., Choi, J. H., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1500108 · Cited by 79
Vento, J. A., Mulgaonkar, A., Woolford, L., Nham, K., Christie, A. L., Bagrodia, A., de Leon, A. D., Hannan, R., Bowman, I. A., McKay, R. M., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0607-z · Cited by 77
Wang, X., Bao, Z., Zhang, X., Li, F., Lai, T., Cao, C., Chen, Z., Li, W., Shen, H., & Ying, S. (2017) · Oncotarget · doi:10.18632/oncotarget.18316 · Cited by 76
Ameratunga, M., Chénard-Poirier, M., Candilejo, I. M., Pedregal, M., Lui, A., Dolling, D. I., Aversa, C., Garces, A. I., Ang, J. E., Banerji, U., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.11.012 · Cited by 76
Drug discovery targeting the mTOR pathway
Martelli, A. M., Buontempo, F., & McCubrey, J. A. (2018) · Clinical Science · doi:10.1042/cs20171158 · Cited by 77
Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors
Awadalla, M., Golden, D. L. A., Mahmood, S., Alvi, R. M., Mercaldo, N. D., Hassan, M. Z. O., Banerji, D., Rokicki, A., Mulligan, C. P., Murphy, S., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0535-y · Cited by 78
Reustle, A., Marco, M. D., Meyerhoff, C., Nelde, A., Walz, J. S., Winter, S., Kandabarau, S., Büttner, F., Haag, M., Backert, L., et al. (2020) · Genome Medicine · doi:10.1186/s13073-020-00731-8 · Cited by 78
Wang, Y., Zhang, X., Wang, Y., Zhao, W., Li, H., Zhang, L., Li, X., Zhang, T., Zhang, H., Huang, H., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.004 · Cited by 76
Mollica, V., Santoni, M., Matrana, M. R., Basso, U., Giorgi, U. D., Rizzo, A., Maruzzo, M., Marchetti, A., Rosellini, M., Bleve, S., et al. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00861-y · Cited by 76
Immunotherapy of glioblastoma: Recent advances and future prospects
Yuan, B., Wang, G., Tang, X., Tong, A., & Zhou, L. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2055417 · Cited by 77
Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management
Prieux‐Klotz, C., Dior, M., Damotte, D., Dréanic, J., Brieau, B., Brézault, C., Abitbol, V., Chaussade, S., & Coriat, R. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0495-4 · Cited by 76
Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy
Bellesœur, A., Carton, E., Alexandre, J., Goldwasser, F., & Huillard, O. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s109640 · Cited by 76
Korehisa, S., Oki, E., Iimori, M., Nakaji, Y., Shimokawa, M., Saeki, H., Okano, S., Oda, Y., & Maehara, Y. (2017) · International Journal of Cancer · doi:10.1002/ijc.31107 · Cited by 76
Signoretti, S., Flaifel, A., Chen, Y., & Reuter, V. E. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.2259 · Cited by 76
Extracellular Vesicles and Tumor-Immune Escape: Biological Functions and Clinical Perspectives
Raimondo, S., Pucci, M., Alessandro, R., & Fontana, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072286 · Cited by 79
Zschäbitz, S., Lasitschka, F., Hadaschik, B., Hofheinz, R.-D., Jentsch-Ullrich, K., Grüner, M., Jäger, D., & Grüllich, C. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.033 · Cited by 75
Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction
Kanz, B. A., Pollack, M. H., Johnpulle, R., Puzanov, I., Horn, L., Morgans, A., Sosman, J. A., Rapisuwon, S., Conry, R. M., Eroglu, Z., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0166-5 · Cited by 75
Self-citationCurrent Insights into Long Non-Coding RNAs in Renal Cell Carcinoma
Seles, M., Hutterer, G. C., Kiesslich, T., Pummer, K., Berindan‐Neagoe, I., Perakis, S. O., Schwarzenbacher, D., Stotz, M., Gerger, A., & Pichler, M. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040573 · Cited by 75
Targeting the PD-1 pathway: a new hope for gastrointestinal cancers
Bi̇lgi̇n, B., Şendur, M. A. N., Akıncı, M. B., Dede, D. Ş., & Yalçın, B. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1279132 · Cited by 75
Laubli, H. P., Hench, J., Stanczak, M. A., Heijnen, I., Papachristofilou, A., Frank, S., Zippelius, A., & Stenner, F. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0249-y · Cited by 76
Role of Immunotherapy in Head and Neck Cancer
Ling, D. C., Bakkenist, C. J., Ferris, R. L., & Clump, D. A. (2017) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2017.08.009 · Cited by 75
Omarini, C., Guaitoli, G., Pipitone, S., Moscetti, L. I., Cortesi, L., Cascinu, S., & Piacentini, F. (2018) · Cancer Management and Research · doi:10.2147/cmar.s146658 · Cited by 75
Immunotherapy in breast cancer
Bayraktar, S., Batoo, S. A., Okuno, S. H., & Glück, S. (2019) · Journal of Carcinogenesis · doi:10.4103/jcar.jcar_2_19 · Cited by 77
Meyers, D. E., Stukalin, I., Vallerand, I. A., Lewinson, R. T., Suo, A. E., Dean, M. L., North, S. A., Pabani, A., Cheng, T., Heng, D. Y. C., et al. (2019) · Cancers · doi:10.3390/cancers11111713 · Cited by 77
Shimozaki, K., Sukawa, Y., Beppu, N., Kurihara, I., Suzuki, S., Mizuno, R., Funakoshi, T., Ikemura, S., Tsugaru, K., Togasaki, K., et al. (2020) · Cancer Management and Research · doi:10.2147/cmar.s247554 · Cited by 77
News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors
Melaiu, O., Lucarini, V., Giovannoni, R., Fruci, D., & Gemignani, F. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.001 · Cited by 76
Immune Checkpoint Inhibitor-Related Pneumonitis
Gomatou, G., Tzilas, V., Kotteas, E., Syrigos, K., & Bouros, D. (2020) · Respiration · doi:10.1159/000509941 · Cited by 75
Kim, C. M., Lee, J. B., Shin, S. J., Ahn, J. B., Lee, M., & Kim, H. S. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100577 · Cited by 77
Dietary factors and their influence on immunotherapy strategies in oncology: a comprehensive review
Golonko, A., Pienkowski, T., Świsłocka, R., Orzechowska, S., Marszałek, K., Szczerbiński, Ł., Swiergiel, A. H., & Lewandowski, W. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06641-6 · Cited by 77
T cell Bim levels reflect responses to anti–PD-1 cancer therapy
Dronca, R. S., Liu, X., Harrington, S. M., Chen, L., Cao, S., Kottschade, L. A., McWilliams, R. R., Block, M. S., Nevala, W. K., Thompson, M. A., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.86014 · Cited by 75
Motzer, R. J., Escudier, B. J., Powles, T. B., Scheffold, C., & Choueiri, T. K. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0061-6 · Cited by 75
Self-citationDerosa, L., Routy, B., Kroemer, G., & Zitvogel, L. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1434468 · Cited by 74
Barbieri, C. E., Chinnaiyan, A. M., Lerner, S. P., Swanton, C., & Rubin, M. A. (2016) · European Urology · doi:10.1016/j.eururo.2016.08.024 · Cited by 74
Calvo, E., Schmidinger, M., Heng, D. Y. C., Grünwald, V., & Escudier, B. J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.09.002 · Cited by 74
Self-citationGender-Related Approach to Kidney Cancer Management: Moving Forward
Mancini, M., Righetto, M., & Baggio, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093378 · Cited by 76
Awad, M. M., Jones, R. E., Liu, H., Lizotte, P. H., Ivanova, E. V., Kulkarni, M. M., Herter-Sprie, G. S., Liao, X., Santos, A. A., Bittinger, M. A., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0171 · Cited by 75
Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don’t Forget the Fuel
Irving, M. B., de Silly, R. V., Scholten, K. B. J., Dilek, N., & Coukos, G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00267 · Cited by 76
Seeber, A., Klinglmair, G., Fritz, J., Steinkohl, F., Zimmer, K., Aigner, F., Horninger, W., Gastl, G. A., Zelger, B. G., Brunner, A., et al. (2018) · Cancer Science · doi:10.1111/cas.13560 · Cited by 74
Trial watch: immune checkpoint blockers for cancer therapy
Vanpouille-Box, C., Lhuillier, C., Bezu, L., Aranda, F., Yamazaki, T., Kepp, O., Fucikova, J., Spisek, R., Demaria, S., Formenti, S. C., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1373237 · Cited by 73
Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review
Tannir, N. M., Pal, S. K., & Atkins, M. B. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0534 · Cited by 74
Kim, E., & Zschiedrich, S. (2018) · Frontiers in Pediatrics · doi:10.3389/fped.2018.00016 · Cited by 77
Nivolumab for the treatment of colorectal cancer
Smith, K. M., & Desai, J. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1480942 · Cited by 73
Gyawali, B., Hey, S. P., & Kesselheim, A. S. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.0416 · Cited by 73
Targeting the PD-1/PD-L1 Axis for the Treatment of Non-Small-Cell Lung Cancer
Meyers, D. E., Bryan, P., Banerji, S. O., & Morris, D. G. (2018) · Current Oncology · doi:10.3747/co.25.3976 · Cited by 74
Bocanegra, A., Fernández-Hinojal, G., Zuazo, M., Arasanz, H., García-Granda, M. J., Hernandez, C., Ibáñez-Vea, M., Hernández‐Marín, B., Martínez-Aguillo, M., Lecumberri, M. J., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071631 · Cited by 73
Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies
Sakakida, T., Ishikawa, T., Chihara, Y., Harita, S., Uchino, J., Tabuchi, Y., Komori, S., Asai, J., Narukawa, T., Arai, A., et al. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02214-8 · Cited by 73
Nassar, A. H., Mouw, K. W., Jegede, O. A., Shinagare, A. B., Kim, J., Liu, C., Pomerantz, M. M., Harshman, L. C., Allen, E. M. V., Wei, X. X., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0686-0 · Cited by 74
Self-citationPredictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer
Raimondi, A., Sepe, P., Zattarin, E., Mennitto, A., Stellato, M., Claps, M., Guadalupi, V., Verzoni, E., de Braud, F., & Procopio, G. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01644 · Cited by 76
Self-citationBlood-Brain Barrier Disruption in Neuro-Oncology: Strategies, Failures, and Challenges to Overcome
Karmur, B. S., Philteos, J., Abbasian, A., Zacharia, B. E., Lipsman, N., Levin, V. A., Grossman, S. A., & Mansouri, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.563840 · Cited by 73
Takamatsu, K., Tanaka, N., Hakozaki, K., Takahashi, R., Teranishi, Y., Murakami, T., Kufukihara, R., Niwa, N., Mikami, S., Shinojima, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25865-0 · Cited by 76
Radiotherapy: Brightness and darkness in the era of immunotherapy
Zhai, D., An, D., Wan, C., & Yang, K. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101366 · Cited by 73
Wang, I., Song, L., Wang, B. Y., Kalebasty, A. R., Uchio, E., & Zi, X. (2022) · PubMed · Cited by 88
Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups
de Velasco, G., Miao, D., Voss, M. H., Hakimi, A. A., Hsieh, J. J.-D., Tannir, N. M., Tamboli, P., Appleman, L. J., Rathmell, W. K., Allen, E. M. V., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0110 · Cited by 78
Self-citationAndersen, R. S., Westergaard, M. C. W., Kjeldsen, J. W., Müller, A., Pedersen, N. W., Hadrup, S. R., Met, Ö., Seliger, B., Kromann‐Andersen, B., Hasselager, T., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0467 · Cited by 73
Umezu, D., Okada, N., Sakoda, Y., Adachi, K., Ojima, T., Yamaue, H., Eto, M., & Tamada, K. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2263-4 · Cited by 75
Role of myeloid cells in the immunosuppressive microenvironment in gliomas
Locarno, C. V., Simonelli, M., Carenza, C., Capucetti, A., Stanzani, E., Lorenzi, E., Persico, P., Bella, S. D., Passoni, L., Mavilio, D., et al. (2019) · Immunobiology · doi:10.1016/j.imbio.2019.10.002 · Cited by 74
Mills, M. N., Figura, N. B., Arrington, J. A., Yu, H.-H. M., Etame, A. B., Vogelbaum, M. A., Soliman, H. H., Czerniecki, B. J., Forsyth, P. A., Han, H. S., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05552-2 · Cited by 75
Next generation immune-checkpoints for cancer therapy
Donini, C., D’Ambrosio, L., Grignani, G., Aglietta, M., & Sangiolo, D. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.02.79 · Cited by 74
The Role of DNA Methylation in Renal Cell Carcinoma
Lasseigne, B. N., & Brooks, J. D. (2018) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-018-0337-9 · Cited by 75
Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges
McKean, W. B., Moser, J. C., Rimm, D. L., & Hu‐Lieskovan, S. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280571 · Cited by 74
Immunotherapy in Older Adults With Cancer
Presley, C. J., Gomes, F., Burd, C. E., Kanesvaran, R., & Wong, M. L. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00138 · Cited by 72
Xu, J., Zheng, Q., Cheng, X. C., Hu, S., Zhang, C., Zhou, X., Sun, P., Wang, W., Su, Z., Zou, T., et al. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01101-1 · Cited by 72
Transitioning single-cell genomics into the clinic
Lim, J. W. Y., Chin, V. T., Fairfax, K. A., Moutinho, C., Suan, D., Ji, H. P., & Powell, J. E. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-023-00613-w · Cited by 74
Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma
Meng, L., Collier, K. A., Wang, P., Li, Z., Monk, P., Mortazavi, A., Hu, Z., Spakowicz, D. J., Zheng, L., & Yang, Y. (2023) · Cells · doi:10.3390/cells13010034 · Cited by 81
Lucas, C. G., Mirchia, K., Seo, K., Najem, H., Chen, W., Zakimi, N., Foster, K. J., Eaton, C. D., Cady, M. A., Choudhury, A., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01747-1 · Cited by 72
Insulin-like growth factor-1 signaling in renal cell carcinoma
Tracz, A., Szczylik, C. A., Porta, C., & Czarnecka, A. M. (2016) · BMC Cancer · doi:10.1186/s12885-016-2437-4 · Cited by 73
Drug-biomarker co-development in oncology – 20 years and counting
Twomey, J. D., Brahme, N. N., & Zhang, B. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.02.002 · Cited by 75
Betanzos, C. M., Lee, H., Ericsson, P. I. G., Balko, J. M., Johnson, D. B., Zimmerman, L. J., & Liebler, D. C. (2017) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra117.000037 · Cited by 73
Ueda, K., Suekane, S., Kurose, H., Chikui, K., Nakiri, M., Nishihara, K., Matsuo, M., Kawahara, A., Yano, H., & Igawa, T. (2018) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2018.07.003 · Cited by 72
Wang, Y., Ma, R., Liu, F., Lee, S. A., & Zhang, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00374 · Cited by 71
Yamazaki, N., Kiyohara, Y., Uhara, H., Uehara, J., Fujimoto, M., Takenouchi, T., Otsuka, M., Uchi, H., Ihn, H., & Minami, H. (2017) · Cancer Science · doi:10.1111/cas.13241 · Cited by 72
Sarcomatoid renal cell carcinoma: Biology and treatment advances
Mouallem, N. R. E., Smith, S. C., & Paul, A. K. R. (2018) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2017.12.012 · Cited by 71
Construction of immune‐related risk signature for renal papillary cell carcinoma
Wang, Z., Song, Q., Yang, Z., Chen, J., Shang, J., & Ju, W. (2018) · Cancer Medicine · doi:10.1002/cam4.1905 · Cited by 71
Microbiota and Cancer: The Emerging Beneficial Role of Bifidobacteria in Cancer Immunotherapy
Longhi, G., van Sinderen, D., Ventura, M., & Turroni, F. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.575072 · Cited by 72
Fukuda, S., Saito, K., Yasuda, Y., Kijima, T., Yoshida, S., Yokoyama, M., Ishioka, J., Matsuoka, Y., Kageyama, Y., & Fujii, Y. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001564 · Cited by 71
Kawazoe, A., Itahashi, K., Yamamoto, N., Kotani, D., Kuboki, Y., Taniguchi, H., Harano, K., Naito, Y., Suzuki, M., Fukutani, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1929 · Cited by 71
Masuda, T., Tanaka, N., Takamatsu, K., Hakozaki, K., Takahashi, R., Anno, T., Kufukihara, R., Shojo, K., Mikami, S., Shinojima, T., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003883 · Cited by 74
Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma
Ingels, A., Campi, R., Umberto Capitanio, A., Amparore, D., Bertolo, R. G., Carbonara, U., Erdem, S., Kara, Ö., Klatte, T., KRIEGMAIR, M. C., et al. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00592-3 · Cited by 74
Sanborn, R. E., Pishvaian, M. J., Callahan, M. K., Weise, A. M., Sikic, B. I., Rahma, O. E., Cho, D. C., Rizvi, N. A., Sznol, M., Lutzky, J., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005147 · Cited by 71
Yu, X., Long, Y., Chen, B., Tong, Y., Shan, M., Jia, X., Hu, C., Liu, M., Zhou, J. Y., Tang, F., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004590 · Cited by 73
Metadata
- Authors
- Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., Castellano, D., Choueiri, T. K., Gurney, H., Donskov, F., Bono, P., Wagstaff, J., Gauler, T. C., Ueda, T., Tomita, Y., Schutz, F. A., Kollmannsberger, C., Larkin, J., Ravaud, A., Simon, J. S., Xu, L.-A., Waxman, I. M., & Sharma, P.
- Affiliations
- Brigham and Women's Hospital (US)
- Institut Gustave Roussy (FR)
- Beth Israel Deaconess Medical Center (US)
- Roswell Park Comprehensive Cancer Center (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
- Stanford Cancer Institute (US)
- University of Washington (US)
- Vanderbilt University Medical Center (US)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Fox Chase Cancer Center (US)
- Hospital Universitario 12 De Octubre (ES)
- Westmead Hospital (AU)
- Aarhus University Hospital (DK)
- University of Helsinki (FI)
- Swansea University (GB)
- Essen University Hospital (DE)
- Chiba Cancer Center (JP)
- Niigata University (JP)
- Beneficência Portuguesa de São Paulo (BR)
- BC Cancer Agency (CA)
- Royal Marsden Hospital (GB)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Bristol-Myers Squibb (United States) (US)
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Motzer, Robert J.
- Escudier, Bernard
- McDermott, David F.
- George, Saby
- Hammers, Hans J.
- Tykodi, Scott S.
- Sosman, Jeffrey A.
- Procopio, Giuseppe
- Plimack, Elizabeth R.
- Castellano, Daniel
- Choueiri, Toni K.
- Gurney, Howard
- Donskov, Frede
- Bono, Petri
- Wagstaff, John
- Gauler, Thomas C.
- Ueda, Takeshi
- Tomita, Yoshihiko
- Schutz, Fabio A.
- Kollmannsberger, Christian
- Larkin, James
- Ravaud, Alain
- Sharma, Padmanee
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-11-05
- Volume
- 373
- Issue
- 19
- Pages
- 1803-1813
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5719487
- OpenAlex
- W2222086386
- Cited by
- 5,807
- References
- 36
- Citations by year
- 2026: 173 · 2025: 255 · 2024: 367 · 2023: 449 · 2022: 535 · 2021: 669 · 2020: 723 · 2019: 669 · 2018: 719 · 2017: 691 · 2016: 511 · 2015: 36
- FWCI
- 515.99
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Lirias (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- nivolumab, everolimus, PD-1 inhibitors, mTOR inhibitors, overall survival, objective response rate, progression-free survival, treatment-related adverse events, anti-angiogenic therapy, immune checkpoint inhibitors, mTOR inhibition, fatigue, anemia, previously treated patients
- MeSH terms
- Everolimus, Nivolumab, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Renal Cell, Female, Humans, Kidney Neoplasms, Male, Middle Aged, Quality of Life, Survival Analysis, Sirolimus, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
